董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Steven P. James | 男 | Lead Independent Director | 58 | 8.73万美元 | 未持股 | 2017-04-25 |
| Wendell Wierenga | 男 | Director | 69 | 未披露 | 未持股 | 2017-04-25 |
| Willard Dere | 男 | Director | 63 | 3.91万美元 | 未持股 | 2017-04-25 |
| Wendell Wierenga | 男 | Director | 69 | 6.23万美元 | 未持股 | 2017-04-25 |
| Nina Kjellson | 女 | Director | 42 | 6.63万美元 | 未持股 | 2017-04-25 |
| Anne M. VanLent | 女 | Director | 69 | 8.21万美元 | 未持股 | 2017-04-25 |
| Linda S. Grais | 女 | President, Chief Executive Officer and Director | 60 | 217.63万美元 | 未持股 | 2017-04-25 |
| Eckard Weber | 男 | Chairman of the Board of Directors | 67 | 8.98万美元 | 未持股 | 2017-04-25 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Stan Bukofzer | 男 | Chief Medical Officer | 61 | 185.79万美元 | 未持股 | 2017-04-25 |
| Michael Byrnes | 男 | Chief Financial Officer and Treasurer | 40 | 91.07万美元 | 未持股 | 2017-04-25 |
| Linda S. Grais | 女 | President, Chief Executive Officer and Director | 60 | 217.63万美元 | 未持股 | 2017-04-25 |
董事简历
中英对照 | 中文 | 英文- Steven P. James
-
Steven P. James，他一直担任我们的首席独立董事（2014年9月以来）。他曾担任Labrys Biologics公司（私人风投初创公司，开发降钙素基因相关肽CGRP的单克隆抗体，用于预防慢性偏头痛）的总裁兼创始首席执行官（从2012年12月到2014年7月被Teva Pharmaceuticals公司收购）。从2004年10月到2012年12月，他曾担任KAI Pharmaceuticals公司（KAI，于2012年被Amgen公司收购）的总裁兼首席执行官。加入KAI公司之前，他曾担任Exelixis公司、Sunesis Pharmaceuticals公司、Isis Pharmaceuticals公司的领导职务。他此前曾担任Landec Corporation、California Biotechnology公司、Eli Lilly & Company的业务开发、营销和综合管理职务。他持有Brown University的生物学学士学位，以及西北大学凯洛格商学院（Northwestern University Kellogg School of Management）的管理硕士学位。他目前也任职于Oncothyreon公司（NASDAQ：ONTY） 的董事会，也是Middlebridge School in Rhode Island的受托委员会成员。
Steven P. James has served as a member of our board of directors since April 2016. From July 2014 to present, Mr. James has been an independent director at several biotechnology companies and served as acting or interim Chief Executive Officer at Antiva Biosciences previously Hera Therapeutics and Pionyr Immunotherapeutics (previously Precision Immune). Mr. James served as President and Chief Executive Officer of Labrys Biologics, from December 2012 until its acquisition by Teva Pharmaceuticals in July 2014. He was President and Chief Executive Officer of KAI Pharmaceuticals, from October 2004 until its acquisition by Amgen in July 2012. He was Senior Vice President, Commercial Operations, at Exelixis, from 2003 until 2004. Previously he held senior business roles at Sunesis Pharmaceuticals and Isis Pharmaceuticals. He began his career in new product planning at Eli Lilly and Company. Mr. James was also a member of the board of directors of Cascadian Therapeutics and Ocera Therapeutics, and is currently a director of Antiva Biosciences, Chrono Therapeutics and Pionyr Immunotherapeutics, where he has been President and Chief Executive Officer since January 2016. Mr. James earned a Bachelor of Arts degree in biology from Brown University and a Masters in Management degree from the Kellogg Graduate School of Management at Northwestern University. - Steven P. James，他一直担任我们的首席独立董事（2014年9月以来）。他曾担任Labrys Biologics公司（私人风投初创公司，开发降钙素基因相关肽CGRP的单克隆抗体，用于预防慢性偏头痛）的总裁兼创始首席执行官（从2012年12月到2014年7月被Teva Pharmaceuticals公司收购）。从2004年10月到2012年12月，他曾担任KAI Pharmaceuticals公司（KAI，于2012年被Amgen公司收购）的总裁兼首席执行官。加入KAI公司之前，他曾担任Exelixis公司、Sunesis Pharmaceuticals公司、Isis Pharmaceuticals公司的领导职务。他此前曾担任Landec Corporation、California Biotechnology公司、Eli Lilly & Company的业务开发、营销和综合管理职务。他持有Brown University的生物学学士学位，以及西北大学凯洛格商学院（Northwestern University Kellogg School of Management）的管理硕士学位。他目前也任职于Oncothyreon公司（NASDAQ：ONTY） 的董事会，也是Middlebridge School in Rhode Island的受托委员会成员。
- Steven P. James has served as a member of our board of directors since April 2016. From July 2014 to present, Mr. James has been an independent director at several biotechnology companies and served as acting or interim Chief Executive Officer at Antiva Biosciences previously Hera Therapeutics and Pionyr Immunotherapeutics (previously Precision Immune). Mr. James served as President and Chief Executive Officer of Labrys Biologics, from December 2012 until its acquisition by Teva Pharmaceuticals in July 2014. He was President and Chief Executive Officer of KAI Pharmaceuticals, from October 2004 until its acquisition by Amgen in July 2012. He was Senior Vice President, Commercial Operations, at Exelixis, from 2003 until 2004. Previously he held senior business roles at Sunesis Pharmaceuticals and Isis Pharmaceuticals. He began his career in new product planning at Eli Lilly and Company. Mr. James was also a member of the board of directors of Cascadian Therapeutics and Ocera Therapeutics, and is currently a director of Antiva Biosciences, Chrono Therapeutics and Pionyr Immunotherapeutics, where he has been President and Chief Executive Officer since January 2016. Mr. James earned a Bachelor of Arts degree in biology from Brown University and a Masters in Management degree from the Kellogg Graduate School of Management at Northwestern University.
- Wendell Wierenga
-
Wendell Wierenga，2014年9月以来，他一直担任我们董事会的成员。他是一个经验丰富的制药执行官，拥有研究、药物发现和药物开发各方面的丰富经验。从2011年6月到2014年2月，他担任Santarus公司（公共生物制药公司，于2014年1月被Salix Pharmaceuticals公司收购）的研发执行副总裁。从2007年到2011年5月，他曾担任Ambit Biosciences Corporation的执行副总裁，负责研发。从2003年到2007年，他曾担任Neurocrine Biosciences公司的负责研发的执行副总裁。从2000年到2003年，他曾担任Syrrx公司的首席执行官。从1990年到2000年，他曾担任Parke-Davis公司（Warner Lambert公司的一个部门）的全球制药科学、技术和发展的副总裁。任职Parke-Davis公司之前，他曾任职Upjohn Co。及其继任公司16年，担任多种职务，最近担任负责发现研究的执行董事。此外，他是XenoPort公司、Cytokinetics公司、Ocera Therapeutics公司、Apricus Biosciences公司、Concert Pharmaceuticals公司的董事。在之前的五年里，他此前也曾任职于Onyx Pharmaceuticals公司的董事会。他持有Hope College的学士学位，以及Stanford University的化学博士学位。
Wendell Wierenga has served as a member of our Board of Directors since February 2011. From June 2011 to January 2014 Dr. Wierenga served as Executive Vice President, Research and Development, at Santarus, Inc., acquired by Salix Inc., which was subsequently acquired by Valeant Pharmaceuticals International, Inc. From 2006 to 2011 he served as Executive Vice President, Research and Development, at Ambit Biosciences Corporation. From 2003 to 2006 he served as Executive Vice President of Research and Development at Neurocrine Biosciences, Inc. From 2000 to 2003 Dr. Wierenga served as Chief Executive Officer of Syrrx, Inc. now part of Takeda Pharmaceutical Company. From 1990 to 2000 he was Senior Vice President of Worldwide Pharmaceutical Sciences, Technologies and Development at Parke-Davis/Warner Lambert (now Pfizer, Inc.). Prior to that, Dr. Wierenga spent 16 years at Upjohn Pharmaceuticals in research and drug discovery roles, most recently as Executive Director of Discovery Research. Dr. Wierenga has served on the Board of Directors of Crinetics Pharmaceuticals since 2014 and Dermata Therapeutics since September 2016. He also served on the Board of Directors of Onyx Pharmaceuticals, Inc. from 1996 to 2013 XenoPort, Inc. from 2001 to August 2016 Ocera Therapeutics, Inc. from December 2013 to December 2018 Anacor Pharmaceuticals, Inc. from September 2014 to July 2016 Apricus Biosciences, Inc. from March 2014 to December 2018 Concert Pharmaceuticals, Inc. from March 2014 to June 2019 and Patara Pharma, Inc. from 2015 to November 2018. Dr. Wierenga holds a B.A. from Hope College and a Ph.D. in Chemistry from Stanford University. - Wendell Wierenga，2014年9月以来，他一直担任我们董事会的成员。他是一个经验丰富的制药执行官，拥有研究、药物发现和药物开发各方面的丰富经验。从2011年6月到2014年2月，他担任Santarus公司（公共生物制药公司，于2014年1月被Salix Pharmaceuticals公司收购）的研发执行副总裁。从2007年到2011年5月，他曾担任Ambit Biosciences Corporation的执行副总裁，负责研发。从2003年到2007年，他曾担任Neurocrine Biosciences公司的负责研发的执行副总裁。从2000年到2003年，他曾担任Syrrx公司的首席执行官。从1990年到2000年，他曾担任Parke-Davis公司（Warner Lambert公司的一个部门）的全球制药科学、技术和发展的副总裁。任职Parke-Davis公司之前，他曾任职Upjohn Co。及其继任公司16年，担任多种职务，最近担任负责发现研究的执行董事。此外，他是XenoPort公司、Cytokinetics公司、Ocera Therapeutics公司、Apricus Biosciences公司、Concert Pharmaceuticals公司的董事。在之前的五年里，他此前也曾任职于Onyx Pharmaceuticals公司的董事会。他持有Hope College的学士学位，以及Stanford University的化学博士学位。
- Wendell Wierenga has served as a member of our Board of Directors since February 2011. From June 2011 to January 2014 Dr. Wierenga served as Executive Vice President, Research and Development, at Santarus, Inc., acquired by Salix Inc., which was subsequently acquired by Valeant Pharmaceuticals International, Inc. From 2006 to 2011 he served as Executive Vice President, Research and Development, at Ambit Biosciences Corporation. From 2003 to 2006 he served as Executive Vice President of Research and Development at Neurocrine Biosciences, Inc. From 2000 to 2003 Dr. Wierenga served as Chief Executive Officer of Syrrx, Inc. now part of Takeda Pharmaceutical Company. From 1990 to 2000 he was Senior Vice President of Worldwide Pharmaceutical Sciences, Technologies and Development at Parke-Davis/Warner Lambert (now Pfizer, Inc.). Prior to that, Dr. Wierenga spent 16 years at Upjohn Pharmaceuticals in research and drug discovery roles, most recently as Executive Director of Discovery Research. Dr. Wierenga has served on the Board of Directors of Crinetics Pharmaceuticals since 2014 and Dermata Therapeutics since September 2016. He also served on the Board of Directors of Onyx Pharmaceuticals, Inc. from 1996 to 2013 XenoPort, Inc. from 2001 to August 2016 Ocera Therapeutics, Inc. from December 2013 to December 2018 Anacor Pharmaceuticals, Inc. from September 2014 to July 2016 Apricus Biosciences, Inc. from March 2014 to December 2018 Concert Pharmaceuticals, Inc. from March 2014 to June 2019 and Patara Pharma, Inc. from 2015 to November 2018. Dr. Wierenga holds a B.A. from Hope College and a Ph.D. in Chemistry from Stanford University.
- Willard Dere
-
Willard Dere，医学博士，自2016年10月起担任我们的董事之一。Dere博士担任内科教授；B.Lue和Hope S.Bettilyon担任糖尿病研究内科主席，个性化健康执行董事，犹他大学健康科学中心临床和转化科学中心的联合首席研究员。在2014年11月重新加入学术界之前，Dere博士在生物制药行业工作了25年。他于2003年加入Amgen公司，在那里他曾担任多种职务，包括全球开发、国际研究与开发主管，以及公司和国际首席医疗官。他曾领导Prolia公司的开发计划和其他几个计划，并于2014年10月退任Amgen公司。他的职业生涯始于1989年任职Eli Lilly公司，并在临床药理学、监管事务以及早期转化和后期临床研究中担任多种不同的全球职务。任职Eli Lilly公司期间，他曾领导Evista and Forteo公司的开发。Dere博士目前在RadiusHealth，Inc.董事会任职。纳斯达克市场代码:RDUS和Biomarin PharmaceuticalInc.（纳斯达克市场代码:BMRN），并担任加州再生医学研究所的科学顾问委员会成员。此前，Dere博士在犹他大学（University of Utah）的教员中任职四年，是美国医师学院（American College of Physicians）的研究员。Dere博士在加州大学戴维斯分校（University of California，Davis）获得工商管理硕士学位。
Willard Dere,has served on board of directors since August 2021 and as lead independent director since November 2024. Dr. Dere currently serves as Chief Advisor and Chief Medical Officer at Angitia since July 2022, and on the board of directors of BioMarin, Seres and Mersana. From November 2014 to August 2022 he served as a director at Radius Health. He also serves on the Scientific Advisory Boards of Surrozen, AliveGen and Heranova Lifesciences. Dr. Dere served as a Professor of Internal Medicine from November 2014 to July 2022 at the University of Utah School of Medicine, and is currently Professor Emeritus, a position he has held since July 2022. Dr. Dere also served as Associate Vice President for Research, Co-Director of The Center for Genomic Medicine and Co-Director of the Utah Clinical and Translational Science Institute at the University of Utah Health Sciences Center during this time period. Before joining the University of Utah, Dr. Dere held various positions at Amgen, Inc., including Senior Vice President of Global Development and Corporate, then International Chief Medical Officer, from July 2003 to October 2014. From 1989 to 2003, Dr. Dere held multiple positions in clinical research, and regulatory affairs and safety at Eli Lilly and Company. He was also an assistant professor from 1989 to 1999 and a clinical associate professor from 1999 to 2009 at the Indiana University School of Medicine. Dr. Dere received his B.A. in history, zoology and M.D. from the University of California, Davis; he completed his postdoctoral training at the University of Utah in internal medicine, and at the University of California, San Francisco in endocrinology and metabolism. - Willard Dere，医学博士，自2016年10月起担任我们的董事之一。Dere博士担任内科教授；B.Lue和Hope S.Bettilyon担任糖尿病研究内科主席，个性化健康执行董事，犹他大学健康科学中心临床和转化科学中心的联合首席研究员。在2014年11月重新加入学术界之前，Dere博士在生物制药行业工作了25年。他于2003年加入Amgen公司，在那里他曾担任多种职务，包括全球开发、国际研究与开发主管，以及公司和国际首席医疗官。他曾领导Prolia公司的开发计划和其他几个计划，并于2014年10月退任Amgen公司。他的职业生涯始于1989年任职Eli Lilly公司，并在临床药理学、监管事务以及早期转化和后期临床研究中担任多种不同的全球职务。任职Eli Lilly公司期间，他曾领导Evista and Forteo公司的开发。Dere博士目前在RadiusHealth，Inc.董事会任职。纳斯达克市场代码:RDUS和Biomarin PharmaceuticalInc.（纳斯达克市场代码:BMRN），并担任加州再生医学研究所的科学顾问委员会成员。此前，Dere博士在犹他大学（University of Utah）的教员中任职四年，是美国医师学院（American College of Physicians）的研究员。Dere博士在加州大学戴维斯分校（University of California，Davis）获得工商管理硕士学位。
- Willard Dere,has served on board of directors since August 2021 and as lead independent director since November 2024. Dr. Dere currently serves as Chief Advisor and Chief Medical Officer at Angitia since July 2022, and on the board of directors of BioMarin, Seres and Mersana. From November 2014 to August 2022 he served as a director at Radius Health. He also serves on the Scientific Advisory Boards of Surrozen, AliveGen and Heranova Lifesciences. Dr. Dere served as a Professor of Internal Medicine from November 2014 to July 2022 at the University of Utah School of Medicine, and is currently Professor Emeritus, a position he has held since July 2022. Dr. Dere also served as Associate Vice President for Research, Co-Director of The Center for Genomic Medicine and Co-Director of the Utah Clinical and Translational Science Institute at the University of Utah Health Sciences Center during this time period. Before joining the University of Utah, Dr. Dere held various positions at Amgen, Inc., including Senior Vice President of Global Development and Corporate, then International Chief Medical Officer, from July 2003 to October 2014. From 1989 to 2003, Dr. Dere held multiple positions in clinical research, and regulatory affairs and safety at Eli Lilly and Company. He was also an assistant professor from 1989 to 1999 and a clinical associate professor from 1999 to 2009 at the Indiana University School of Medicine. Dr. Dere received his B.A. in history, zoology and M.D. from the University of California, Davis; he completed his postdoctoral training at the University of Utah in internal medicine, and at the University of California, San Francisco in endocrinology and metabolism.
- Wendell Wierenga
-
Wendell Wierenga于2016年9月成为董事。从2011年6月到2014年1月，Wierenga博士担任Santarus，Inc.（上市生物制药公司，2014年1月被Salix Pharmaceuticals，Inc.收购）的执行副总裁兼研究与开发。从2004年7月到2011年5月，Wierenga博士担任Ambit Biosciences Corporation and NeurocrineBiosciences，Inc.的执行副总裁、研究与开发。纳斯达克:NBIX。加入Neurocrine之前，从1999年8月到2004年6月，他担任SyrRx，Inc.的首席执行官，在那里他建立了一家早期生物技术公司，该公司于2005年被Takeda Pharmaceutical Company Limited收购。从1990年到2000年，何博士也是一名老先生。Parke Davis/Warner Lambert的研究副总裁，当时该公司被辉瑞公司收购，在此之前从1974年到1990年在Upjohn Pharmaceuticals担任多个研究职位。维伦加博士在斯坦福大学获得化学博士学位，在密歇根荷兰的希望学院获得文学学士学位。他目前是Crinetics（NASDAQ:CRNX）的董事会主席，也是Cytkinetics，Inc.（NASDAQ:CYTK）的董事会成员。最近担任Anacor Pharmaceuticals Inc.和XenoPort，Inc.的董事会成员，此前他们分别出售给辉瑞公司和Arbor Pharmaceuticals，LLC。
Wendell Wierenga became a director in September 2016. From June 2011 to January 2014, Dr. Wierenga served as Executive Vice President, Research and Development at Santar, Inc., a public biopharmaceutical company that was acquired by Salix Pharmaceuticals, Inc. in January 2014. From July 2004 to May 2011, Dr. Wierenga served as Executive Vice President, Research and Development at Ambit Biosciences Corporation and Neurocrine Biosciences, Inc. (Nasdaq: NBIX). Prior to Neurocrine, from Augt 1999 to June 2004 he served as the Chief Executive Officer for Syrrx, Inc. where he built an early stage biotech company which was acquired by Takeda Pharmaceutical Company Limited in 2005. From 1990 to 2000, Dr. He also was Sr. VP of Research at Parke Davis/Warner Lambert, when it was acquired by Pfizer Inc. and prior to that held vario positions in research at Upjohn Pharmaceuticals from 1974 1990. Dr. Wierenga earned his Ph.D. in chemistry from Stanford University and his B.A. from Hope College in Holland, Michigan. Dr. Wierenga is currently the chair of the Board of Directors of Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) and is also a member of the Board of Directors of Cytokinetics, Inc. (Nasdaq: CYTK). He was most recently on the Board of Directors for Anacor Pharmaceuticals Inc. and XenoPort, Inc. prior to their sales to Pfizer Inc. and Arbor Pharmaceuticals, LLC, respectively. - Wendell Wierenga于2016年9月成为董事。从2011年6月到2014年1月，Wierenga博士担任Santarus，Inc.（上市生物制药公司，2014年1月被Salix Pharmaceuticals，Inc.收购）的执行副总裁兼研究与开发。从2004年7月到2011年5月，Wierenga博士担任Ambit Biosciences Corporation and NeurocrineBiosciences，Inc.的执行副总裁、研究与开发。纳斯达克:NBIX。加入Neurocrine之前，从1999年8月到2004年6月，他担任SyrRx，Inc.的首席执行官，在那里他建立了一家早期生物技术公司，该公司于2005年被Takeda Pharmaceutical Company Limited收购。从1990年到2000年，何博士也是一名老先生。Parke Davis/Warner Lambert的研究副总裁，当时该公司被辉瑞公司收购，在此之前从1974年到1990年在Upjohn Pharmaceuticals担任多个研究职位。维伦加博士在斯坦福大学获得化学博士学位，在密歇根荷兰的希望学院获得文学学士学位。他目前是Crinetics（NASDAQ:CRNX）的董事会主席，也是Cytkinetics，Inc.（NASDAQ:CYTK）的董事会成员。最近担任Anacor Pharmaceuticals Inc.和XenoPort，Inc.的董事会成员，此前他们分别出售给辉瑞公司和Arbor Pharmaceuticals，LLC。
- Wendell Wierenga became a director in September 2016. From June 2011 to January 2014, Dr. Wierenga served as Executive Vice President, Research and Development at Santar, Inc., a public biopharmaceutical company that was acquired by Salix Pharmaceuticals, Inc. in January 2014. From July 2004 to May 2011, Dr. Wierenga served as Executive Vice President, Research and Development at Ambit Biosciences Corporation and Neurocrine Biosciences, Inc. (Nasdaq: NBIX). Prior to Neurocrine, from Augt 1999 to June 2004 he served as the Chief Executive Officer for Syrrx, Inc. where he built an early stage biotech company which was acquired by Takeda Pharmaceutical Company Limited in 2005. From 1990 to 2000, Dr. He also was Sr. VP of Research at Parke Davis/Warner Lambert, when it was acquired by Pfizer Inc. and prior to that held vario positions in research at Upjohn Pharmaceuticals from 1974 1990. Dr. Wierenga earned his Ph.D. in chemistry from Stanford University and his B.A. from Hope College in Holland, Michigan. Dr. Wierenga is currently the chair of the Board of Directors of Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) and is also a member of the Board of Directors of Cytokinetics, Inc. (Nasdaq: CYTK). He was most recently on the Board of Directors for Anacor Pharmaceuticals Inc. and XenoPort, Inc. prior to their sales to Pfizer Inc. and Arbor Pharmaceuticals, LLC, respectively.
- Nina Kjellson
-
Nina Kjellson，自2014年5月起担任董事；是InterWest Partners（大型多元化风险资本公司）的一般合伙人，她从2002年起在该公司任职。她在加入InterWest之前，1999年至2000年间担任Bay City Capital（生命科学商业银行）的投资经理，也是Oracle Partners（对冲基金，关注医疗保健）的研究助理。她于1997年8月至1999年9月间在the Kaiser Family Foundation进行保健政策和调查研究；目前是Alvine Pharmaceuticals, Inc., Cebix, Inc., Eiger Biopharmaceuticals, Inc., Lycera Corp., Ocera Therapeutics Inc.， 和Welltok, Inc.的董事。她获得了Stanford University的人类生物学学士学位。
Nina Kjellson has served as one of our directors since the closing of the Merger. Ms. Kjellson served as a member of the board of directors of Private Ocera from June 2011 to July 2013. Ms. Kjellson is a managing director at Canaan Partners, a venture capital firm, where she has been employed since September 2015. From June 2002 to August 2015 she served as a principal and General Partner at InterWest Partners, a venture capital firm. From June 2000 to June 2002 she served as an investment manager at Bay City Capital, a life sciences merchant bank, and from October 1999 to June 2000 as a research associate at Oracle Partners, a healthcare‑focused hedge fund. From August 1997 to September 1999 Ms. Kjellson conducted health policy and survey research with the Kaiser Family Foundation, a private foundation focusing on healthcare issues. She holds a B.A. in Human Biology from Stanford University. Ms. Kjellson has served as a member of the previously privately-held Eiger BioPharmaceuticals, Inc., now listed on the NASDAQ NASDAQ:EIGR, a biopharmaceutical company focused on the development of novel products for the treatment of orphan diseases. Ms. Kjellson also served on the board of directors of Trius Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of antibiotics for serious infections formerly listed on the NASDAQ, from February 2007 until its acquisition by Cubist Pharmaceuticals, Inc. in September 2013. - Nina Kjellson，自2014年5月起担任董事；是InterWest Partners（大型多元化风险资本公司）的一般合伙人，她从2002年起在该公司任职。她在加入InterWest之前，1999年至2000年间担任Bay City Capital（生命科学商业银行）的投资经理，也是Oracle Partners（对冲基金，关注医疗保健）的研究助理。她于1997年8月至1999年9月间在the Kaiser Family Foundation进行保健政策和调查研究；目前是Alvine Pharmaceuticals, Inc., Cebix, Inc., Eiger Biopharmaceuticals, Inc., Lycera Corp., Ocera Therapeutics Inc.， 和Welltok, Inc.的董事。她获得了Stanford University的人类生物学学士学位。
- Nina Kjellson has served as one of our directors since the closing of the Merger. Ms. Kjellson served as a member of the board of directors of Private Ocera from June 2011 to July 2013. Ms. Kjellson is a managing director at Canaan Partners, a venture capital firm, where she has been employed since September 2015. From June 2002 to August 2015 she served as a principal and General Partner at InterWest Partners, a venture capital firm. From June 2000 to June 2002 she served as an investment manager at Bay City Capital, a life sciences merchant bank, and from October 1999 to June 2000 as a research associate at Oracle Partners, a healthcare‑focused hedge fund. From August 1997 to September 1999 Ms. Kjellson conducted health policy and survey research with the Kaiser Family Foundation, a private foundation focusing on healthcare issues. She holds a B.A. in Human Biology from Stanford University. Ms. Kjellson has served as a member of the previously privately-held Eiger BioPharmaceuticals, Inc., now listed on the NASDAQ NASDAQ:EIGR, a biopharmaceutical company focused on the development of novel products for the treatment of orphan diseases. Ms. Kjellson also served on the board of directors of Trius Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of antibiotics for serious infections formerly listed on the NASDAQ, from February 2007 until its acquisition by Cubist Pharmaceuticals, Inc. in September 2013.
- Anne M. VanLent
-
Anne M. VanLent从2013年5月开始担任该公司的董事会董事。 VanLent女士目前担任 AMV Advisors的总裁，其为新兴成长生命科学公司提供公司战略与财务咨询服务。从2002年5月到2008年4月，VanLent女士担任Barrier Therapeutics, Inc.的执行副总裁和首席财务官，这是一家上市的制药公司，其开发并销售皮肤病处方药物产品。从1997年7月到2001年10月，她担任Sarnoff Corporation投资组合管理部执行副总裁，这是一家多学科的研发公司。从1985年到1993年，她担任Liposome Company, Inc.的副总裁兼首席财务官，这是一家上市的生物制药公司。VanLent女士目前担任以下公司的董事和审计委员会主席：Aegerion Pharmaceuticals, Inc.、Ocera Pharmaceuticals, Inc.和Onconova Therapeutics, Inc.，以上公司均为上市公司。在过去5年间VanLent女士还担任Penwest Pharmaceuticals Co。的董事直到2010年，并担任Integra Life Sciences的董事到2012年5月。VanLent女士学位在曼荷莲学院（Mount Holyoke College）获得物理学文学学士学位。VanLent女士丰富的领导与财务经验，以及担任生命科学行业的多个公众公司的董事、审计委员会委员和审计委员会主席的丰富经验，得出的结论是：她应该担任该公司的董事。
Anne M. VanLent has served as a member of our board of directors since 2013. Ms. VanLent is President of AMV Advisors, providing corporate strategy and financial consulting services to emerging growth life sciences companies. Ms. VanLent also serves as a director and audit committee chair of Applied Genetics Technologies Corporation Nasdaq: AGTC and as a director of Trevi Therapeutics, Inc. Ms. VanLent was the Executive Vice President and Chief Financial Officer of Barrier Therapeutics, Inc., a publicly-traded pharmaceutical company that develops and markets prescription dermatology products, from May 2002 through April 2008. From July 1997 to October 2001 she was the Executive Vice President - Portfolio Management for Sarnoff Corporation, a multidisciplinary research and development firm. From 1985 to 1993 she served as Senior Vice President and Chief Financial Officer of The Liposome Company, Inc., a publicly-traded biopharmaceutical company. During the past five years, Ms. VanLent served as a director, audit committee chair and nominating and governance committee chair of Ocera Pharmaceuticals, Inc. from March 2011 to December 2017 a director of Novelion Pharmaceuticals, Inc. (formerly Aegerion Pharmaceuticals, Inc.) from March 2013 to June 2017 and of Onconova Therapeutics, Inc. from July 2013 to May 2016. Ms. VanLent received a B.A. in Physics from Mount Holyoke College. - Anne M. VanLent从2013年5月开始担任该公司的董事会董事。 VanLent女士目前担任 AMV Advisors的总裁，其为新兴成长生命科学公司提供公司战略与财务咨询服务。从2002年5月到2008年4月，VanLent女士担任Barrier Therapeutics, Inc.的执行副总裁和首席财务官，这是一家上市的制药公司，其开发并销售皮肤病处方药物产品。从1997年7月到2001年10月，她担任Sarnoff Corporation投资组合管理部执行副总裁，这是一家多学科的研发公司。从1985年到1993年，她担任Liposome Company, Inc.的副总裁兼首席财务官，这是一家上市的生物制药公司。VanLent女士目前担任以下公司的董事和审计委员会主席：Aegerion Pharmaceuticals, Inc.、Ocera Pharmaceuticals, Inc.和Onconova Therapeutics, Inc.，以上公司均为上市公司。在过去5年间VanLent女士还担任Penwest Pharmaceuticals Co。的董事直到2010年，并担任Integra Life Sciences的董事到2012年5月。VanLent女士学位在曼荷莲学院（Mount Holyoke College）获得物理学文学学士学位。VanLent女士丰富的领导与财务经验，以及担任生命科学行业的多个公众公司的董事、审计委员会委员和审计委员会主席的丰富经验，得出的结论是：她应该担任该公司的董事。
- Anne M. VanLent has served as a member of our board of directors since 2013. Ms. VanLent is President of AMV Advisors, providing corporate strategy and financial consulting services to emerging growth life sciences companies. Ms. VanLent also serves as a director and audit committee chair of Applied Genetics Technologies Corporation Nasdaq: AGTC and as a director of Trevi Therapeutics, Inc. Ms. VanLent was the Executive Vice President and Chief Financial Officer of Barrier Therapeutics, Inc., a publicly-traded pharmaceutical company that develops and markets prescription dermatology products, from May 2002 through April 2008. From July 1997 to October 2001 she was the Executive Vice President - Portfolio Management for Sarnoff Corporation, a multidisciplinary research and development firm. From 1985 to 1993 she served as Senior Vice President and Chief Financial Officer of The Liposome Company, Inc., a publicly-traded biopharmaceutical company. During the past five years, Ms. VanLent served as a director, audit committee chair and nominating and governance committee chair of Ocera Pharmaceuticals, Inc. from March 2011 to December 2017 a director of Novelion Pharmaceuticals, Inc. (formerly Aegerion Pharmaceuticals, Inc.) from March 2013 to June 2017 and of Onconova Therapeutics, Inc. from July 2013 to May 2016. Ms. VanLent received a B.A. in Physics from Mount Holyoke College.
- Linda S. Grais
-
Linda S. Grais，自2019年1月起担任Corvus Pharmaceuticals, Inc.董事会成员。Grais博士此前于2012年6月至2017年12月担任Ocera医疗公司总裁兼首席执行官，并于2008年1月至2017年12月担任公司董事会成员。在加入Ocera之前，Grais博士曾于2005年5月至2011年2月担任风险投资公司InterWest Partners的管理成员。从1998年7月到2003年7月，Grais博士是SGX Pharmaceuticals Inc.的创始人和执行副总裁，SGX Pharmaceuticals Inc.是一家专注于癌症新疗法的药物发现公司。在此之前，她是Wilson Sonsini Goodrich & Rosati的公司律师，在风险融资、公开发行和战略合作伙伴关系等领域执业。在从事法律工作之前，Grais博士曾在加州大学旧金山分校担任内科和重症监护的临床助理教授。她目前在公共合同研究机构ICON plc、私营医疗保健服务公司Collective Health和私营生物技术公司Iolyx Therapeutics，Inc.的董事会任职。Grais博士获得了耶鲁大学的学士学位、耶鲁大学医学院的医学博士学位和斯坦福大学法学院的法学博士学位。
Linda S. Grais,has served as a member of Corvus Pharmaceuticals, Inc. Board since January 2019. Dr. Grais previously served as President and Chief Executive Officer of Ocera Therapeutics, Inc. from June 2012 to December 2017 and as a member of its board of directors from January 2008 through December 2017. Prior to her employment by Ocera, Dr. Grais served as a managing member at InterWest Partners, a venture capital firm, from May 2005 until February 2011. From July 1998 to July 2003, Dr. Grais was a founder and executive vice president of SGX Pharmaceuticals Inc., a drug discovery company focusing on new treatments for cancer. Prior to that, she was a corporate attorney at Wilson Sonsini Goodrich & Rosati, where she practiced in such areas as venture financings, public offerings and strategic partnerships. Before practicing law, Dr. Grais worked as an assistant clinical professor of Internal Medicine and Critical Care at the University of California, San Francisco. She currently serves on the board of directors of ICON plc, a public contract research organization, Collective Health, a private healthcare services company and Iolyx Therapeutics, Inc., a private biotechnology company. Dr. Grais received a B.A. from Yale University, an M.D. from Yale Medical School and a J.D. from Stanford Law School. - Linda S. Grais，自2019年1月起担任Corvus Pharmaceuticals, Inc.董事会成员。Grais博士此前于2012年6月至2017年12月担任Ocera医疗公司总裁兼首席执行官，并于2008年1月至2017年12月担任公司董事会成员。在加入Ocera之前，Grais博士曾于2005年5月至2011年2月担任风险投资公司InterWest Partners的管理成员。从1998年7月到2003年7月，Grais博士是SGX Pharmaceuticals Inc.的创始人和执行副总裁，SGX Pharmaceuticals Inc.是一家专注于癌症新疗法的药物发现公司。在此之前，她是Wilson Sonsini Goodrich & Rosati的公司律师，在风险融资、公开发行和战略合作伙伴关系等领域执业。在从事法律工作之前，Grais博士曾在加州大学旧金山分校担任内科和重症监护的临床助理教授。她目前在公共合同研究机构ICON plc、私营医疗保健服务公司Collective Health和私营生物技术公司Iolyx Therapeutics，Inc.的董事会任职。Grais博士获得了耶鲁大学的学士学位、耶鲁大学医学院的医学博士学位和斯坦福大学法学院的法学博士学位。
- Linda S. Grais,has served as a member of Corvus Pharmaceuticals, Inc. Board since January 2019. Dr. Grais previously served as President and Chief Executive Officer of Ocera Therapeutics, Inc. from June 2012 to December 2017 and as a member of its board of directors from January 2008 through December 2017. Prior to her employment by Ocera, Dr. Grais served as a managing member at InterWest Partners, a venture capital firm, from May 2005 until February 2011. From July 1998 to July 2003, Dr. Grais was a founder and executive vice president of SGX Pharmaceuticals Inc., a drug discovery company focusing on new treatments for cancer. Prior to that, she was a corporate attorney at Wilson Sonsini Goodrich & Rosati, where she practiced in such areas as venture financings, public offerings and strategic partnerships. Before practicing law, Dr. Grais worked as an assistant clinical professor of Internal Medicine and Critical Care at the University of California, San Francisco. She currently serves on the board of directors of ICON plc, a public contract research organization, Collective Health, a private healthcare services company and Iolyx Therapeutics, Inc., a private biotechnology company. Dr. Grais received a B.A. from Yale University, an M.D. from Yale Medical School and a J.D. from Stanford Law School.
- Eckard Weber
-
Eckard Weber， 医学博士。他是Tobira的创始人；2007年我公司成立起，担任董事会成员。2001年起，他担任Domain Associates, LLC的合伙人，该公司是生命科学私人风险资本管理公司。他在药物开发方面有20多年经验。2007至2014年6月，他担任Sonexa Therapeutics的临时首席执行官和董事会主席，该公司是处于萌发阶段的生物制药公司。他还是Ocera Therapeutics, Orexigen Therapeutics和Tragara Pharmaceuticals的董事会主席，以及Adynxx, Domain Elite Holdings和Tobira Therapeutics的董事会成员。他曾是Domain Associates多个投资组合公司的创始首席执行官，包括Acea Pharmaceuticals, Ascenta Therapeutics, Calixa Therapeutics, Cytovia和Novacardia。他曾担任多家公司的董事会主席或董事会成员直至被收购，包括2005年被强生（Johnson & Johnson）收购的Peninsula Pharmaceuticals；2007年被森林实验室（Forest Laboratories）收购的Cerexa和2009年被Cubist Therapeutics, Inc.收购的Calixa Therapeutics。 他还曾担任Conforma Therapeutics （2006年被Biogen-IDEC收购）和Cabrellis Pharmaceuticals （2006年被Pharmion收购）的董事会成员。1995年前，他担任加利福尼亚大学尔弯校区（University of California, Irvine）的药理学终生教授。他是多项专利和专利申请书的发明家或发明家之一，在科学期刊出版130多篇论文。他在德国Kolping Kolleg获得学士学位，在德国乌尔姆大学医学院（University of Ulm Medical School）获得医学博士学位。他在斯坦福大学医学院（Stanford University Medical School）接受神经系统科学博士后课程。
Eckard Weber, M.D. has served as the Chairman of the company's Board of Directors since the closing of the Merger. Dr. Weber was a co-founder of Private Ocera and served as Chief Executive Officer from February 2005 to August 2005 a member of its board of directors from its inception in December 2004 to July 2013 and as the chairman of Private Ocera’s board of directors from 2004 to July 2013. Dr. Weber is also a partner with Domain Associates, L.L.C., a private venture capital management firm focused on life sciences, a position he has held since 2001. Dr. Weber is chairman of the board of Tragara Pharmaceuticals, Inc. Dr. Weber is a member of the board of directors of Adynxx, Inc. and Alyrxx, Inc. During the last five years, Dr. Weber served on the board of Atara Biotherapeutics, Inc. NASDAQ:ATRA, Orexigen Therapeutics, Inc. (NASDAQ:OREX), and Tobira Therapeutics, Inc. (NASDAQ:TBRA). Dr. Weber was chairman of Peninsula Pharmaceuticals, Inc., until the company was sold to Johnson & Johnson in 2005 chairman of Cerexa, Inc., until the company was sold to Forest Laboratories, Inc., in January 2007 chairman of NovaCardia, Inc., until the company was sold to Merck in September 2007 chairman of Calixa Therapeutics until the company was sold to Cubist Pharmaceuticals in December 2009 and a board member of Conforma Therapeutics Corporation and Cabrellis Pharmaceuticals Corporation until they were sold to Biogen-IDEC, Inc., and Pharmion Corporation, respectively. Dr. Weber also has over 20 years of drug discovery and development experience and has been a consultant to biotechnology and pharmaceutical companies. Until 1995 he was a tenured Professor of Pharmacology at the University of California, Irvine. Dr. Weber is the inventor or co-inventor of numerous patents and patent applications, and has published over 130 papers in scientific periodicals. Dr. Weber holds an undergraduate degree from Kolping Kolleg in Germany and an M.D. (Dr. med.) from the University of Ulm Medical School in Germany. He received his postdoctoral training in neuroscience at Stanford University Medical School. - Eckard Weber， 医学博士。他是Tobira的创始人；2007年我公司成立起，担任董事会成员。2001年起，他担任Domain Associates, LLC的合伙人，该公司是生命科学私人风险资本管理公司。他在药物开发方面有20多年经验。2007至2014年6月，他担任Sonexa Therapeutics的临时首席执行官和董事会主席，该公司是处于萌发阶段的生物制药公司。他还是Ocera Therapeutics, Orexigen Therapeutics和Tragara Pharmaceuticals的董事会主席，以及Adynxx, Domain Elite Holdings和Tobira Therapeutics的董事会成员。他曾是Domain Associates多个投资组合公司的创始首席执行官，包括Acea Pharmaceuticals, Ascenta Therapeutics, Calixa Therapeutics, Cytovia和Novacardia。他曾担任多家公司的董事会主席或董事会成员直至被收购，包括2005年被强生（Johnson & Johnson）收购的Peninsula Pharmaceuticals；2007年被森林实验室（Forest Laboratories）收购的Cerexa和2009年被Cubist Therapeutics, Inc.收购的Calixa Therapeutics。 他还曾担任Conforma Therapeutics （2006年被Biogen-IDEC收购）和Cabrellis Pharmaceuticals （2006年被Pharmion收购）的董事会成员。1995年前，他担任加利福尼亚大学尔弯校区（University of California, Irvine）的药理学终生教授。他是多项专利和专利申请书的发明家或发明家之一，在科学期刊出版130多篇论文。他在德国Kolping Kolleg获得学士学位，在德国乌尔姆大学医学院（University of Ulm Medical School）获得医学博士学位。他在斯坦福大学医学院（Stanford University Medical School）接受神经系统科学博士后课程。
- Eckard Weber, M.D. has served as the Chairman of the company's Board of Directors since the closing of the Merger. Dr. Weber was a co-founder of Private Ocera and served as Chief Executive Officer from February 2005 to August 2005 a member of its board of directors from its inception in December 2004 to July 2013 and as the chairman of Private Ocera’s board of directors from 2004 to July 2013. Dr. Weber is also a partner with Domain Associates, L.L.C., a private venture capital management firm focused on life sciences, a position he has held since 2001. Dr. Weber is chairman of the board of Tragara Pharmaceuticals, Inc. Dr. Weber is a member of the board of directors of Adynxx, Inc. and Alyrxx, Inc. During the last five years, Dr. Weber served on the board of Atara Biotherapeutics, Inc. NASDAQ:ATRA, Orexigen Therapeutics, Inc. (NASDAQ:OREX), and Tobira Therapeutics, Inc. (NASDAQ:TBRA). Dr. Weber was chairman of Peninsula Pharmaceuticals, Inc., until the company was sold to Johnson & Johnson in 2005 chairman of Cerexa, Inc., until the company was sold to Forest Laboratories, Inc., in January 2007 chairman of NovaCardia, Inc., until the company was sold to Merck in September 2007 chairman of Calixa Therapeutics until the company was sold to Cubist Pharmaceuticals in December 2009 and a board member of Conforma Therapeutics Corporation and Cabrellis Pharmaceuticals Corporation until they were sold to Biogen-IDEC, Inc., and Pharmion Corporation, respectively. Dr. Weber also has over 20 years of drug discovery and development experience and has been a consultant to biotechnology and pharmaceutical companies. Until 1995 he was a tenured Professor of Pharmacology at the University of California, Irvine. Dr. Weber is the inventor or co-inventor of numerous patents and patent applications, and has published over 130 papers in scientific periodicals. Dr. Weber holds an undergraduate degree from Kolping Kolleg in Germany and an M.D. (Dr. med.) from the University of Ulm Medical School in Germany. He received his postdoctoral training in neuroscience at Stanford University Medical School.
高管简历
中英对照 | 中文 | 英文- Stan Bukofzer
Stan Bukofzer，医学博士，自2016年1月5日起担任我们的首席医疗官。在加入我们之前，Bukofzer博士于2012年6月至2015年9月担任注射输液技术领先提供商好比拉医疗保健公司的首席医疗官。Bukofzer从2007年7月到2012年6月担任Astellas Scientific and Medical Affairs，Inc.Vice President，负责7个治疗领域，包括肿瘤学、免疫学、泌尿学、抗感染药物、皮肤学和心血管。从1995年到2007年，Bukofzer博士在雅培公司担任各种职责递增的职位，最近担任部门Vice President和全球医疗事务主管。Bukofzer博士在南非威特沃特斯兰德大学（University of Witwatersrand）获得医学学位，并接受了内科以及胃肠病学和肝脏学的培训。
Stan Bukofzer, M.D. has served as our Chief Medical Officer since January 5 2016. Prior to joining us, Dr. Bukofzer served as Chief Medical Officer of Hospira, Inc., a leading provider of injectable infusion technologies, from June 2012 through September 2015. From July 2007 to June 2012 Dr. Bukofzer was Vice President of Astellas Scientific and Medical Affairs, Inc. where he had responsibility for seven therapeutic areas including oncology, immunology, urology, anti-infectives, dermatology and cardiovascular. From 1995 to 2007 Dr. Bukofzer worked for Abbott Laboratories in a variety of positions of increasing responsibility, most recently as Divisional Vice President and Head of Global Medical Affairs. Dr. Bukofzer received his medical degree from the University of Witwatersrand in South Africa and was trained in internal medicine, as well as gastroenterology and hepatology.- Stan Bukofzer，医学博士，自2016年1月5日起担任我们的首席医疗官。在加入我们之前，Bukofzer博士于2012年6月至2015年9月担任注射输液技术领先提供商好比拉医疗保健公司的首席医疗官。Bukofzer从2007年7月到2012年6月担任Astellas Scientific and Medical Affairs，Inc.Vice President，负责7个治疗领域，包括肿瘤学、免疫学、泌尿学、抗感染药物、皮肤学和心血管。从1995年到2007年，Bukofzer博士在雅培公司担任各种职责递增的职位，最近担任部门Vice President和全球医疗事务主管。Bukofzer博士在南非威特沃特斯兰德大学（University of Witwatersrand）获得医学学位，并接受了内科以及胃肠病学和肝脏学的培训。
- Stan Bukofzer, M.D. has served as our Chief Medical Officer since January 5 2016. Prior to joining us, Dr. Bukofzer served as Chief Medical Officer of Hospira, Inc., a leading provider of injectable infusion technologies, from June 2012 through September 2015. From July 2007 to June 2012 Dr. Bukofzer was Vice President of Astellas Scientific and Medical Affairs, Inc. where he had responsibility for seven therapeutic areas including oncology, immunology, urology, anti-infectives, dermatology and cardiovascular. From 1995 to 2007 Dr. Bukofzer worked for Abbott Laboratories in a variety of positions of increasing responsibility, most recently as Divisional Vice President and Head of Global Medical Affairs. Dr. Bukofzer received his medical degree from the University of Witwatersrand in South Africa and was trained in internal medicine, as well as gastroenterology and hepatology.
- Michael Byrnes
Michael Byrnes，自2020年12月起担任eFFECTOR Therapeutics, Inc.首席财务官。此前，Byrnes先生自2020年1月起担任Principia Biopharma公司财务高级副总裁，直至2020年9月被赛诺菲收购。在此之前，Byrnes先生于2018年5月至2020年1月担任Alkahest，Inc.的首席财务官，并于2014年12月担任Ocera Therapeutics, Inc.的首席财务官，直至2017年12月被马林克罗制药收购。Byrnes先生于2010年3月至2014年12月担任Maxygen，Inc.的公司财务总监，在此之前，他曾于2000年至2010年在NeurogesX，Inc.、Lipid Sciences，Inc.和飞利浦医疗系统公司ADAC Laboratories，Inc.担任财务职位，职责日益增加。伯恩斯在圣克拉拉大学获得金融学学士学位，在加州州立大学海沃德分校获得工商管理硕士学位。
Michael Byrnes,has served as Effector Therapeutics, Inc. Chief Financial Officer since December 2020. Previously, Mr. Byrnes was Senior Vice President of Finance at Principia Biopharma, Inc. from January 2020 until its acquisition by Sanofi in September 2020. Prior to that, Mr. Byrnes served as Chief Financial Officer of Alkahest, Inc. from May 2018 to January 2020 and Chief Financial Officer of Ocera Therapeutics, Inc., from December 2014 until its acquisition by Mallinckrodt Pharmaceuticals in December 2017. Mr. Byrnes served as Corporate Controller of Maxygen, Inc. from March 2010 to December 2014 and prior to that, held finance positions of increasing responsibility from 2000 to 2010 with NeurogesX, Inc., Lipid Sciences, Inc. and ADAC Laboratories, Inc., a Philips Medical Systems company. Mr. Byrnes received his B.S.C. in Finance from Santa Clara University and an M.B.A. from California State University, Hayward.- Michael Byrnes，自2020年12月起担任eFFECTOR Therapeutics, Inc.首席财务官。此前，Byrnes先生自2020年1月起担任Principia Biopharma公司财务高级副总裁，直至2020年9月被赛诺菲收购。在此之前，Byrnes先生于2018年5月至2020年1月担任Alkahest，Inc.的首席财务官，并于2014年12月担任Ocera Therapeutics, Inc.的首席财务官，直至2017年12月被马林克罗制药收购。Byrnes先生于2010年3月至2014年12月担任Maxygen，Inc.的公司财务总监，在此之前，他曾于2000年至2010年在NeurogesX，Inc.、Lipid Sciences，Inc.和飞利浦医疗系统公司ADAC Laboratories，Inc.担任财务职位，职责日益增加。伯恩斯在圣克拉拉大学获得金融学学士学位，在加州州立大学海沃德分校获得工商管理硕士学位。
- Michael Byrnes,has served as Effector Therapeutics, Inc. Chief Financial Officer since December 2020. Previously, Mr. Byrnes was Senior Vice President of Finance at Principia Biopharma, Inc. from January 2020 until its acquisition by Sanofi in September 2020. Prior to that, Mr. Byrnes served as Chief Financial Officer of Alkahest, Inc. from May 2018 to January 2020 and Chief Financial Officer of Ocera Therapeutics, Inc., from December 2014 until its acquisition by Mallinckrodt Pharmaceuticals in December 2017. Mr. Byrnes served as Corporate Controller of Maxygen, Inc. from March 2010 to December 2014 and prior to that, held finance positions of increasing responsibility from 2000 to 2010 with NeurogesX, Inc., Lipid Sciences, Inc. and ADAC Laboratories, Inc., a Philips Medical Systems company. Mr. Byrnes received his B.S.C. in Finance from Santa Clara University and an M.B.A. from California State University, Hayward.
- Linda S. Grais
Linda S. Grais，自2019年1月起担任Corvus Pharmaceuticals, Inc.董事会成员。Grais博士此前于2012年6月至2017年12月担任Ocera医疗公司总裁兼首席执行官，并于2008年1月至2017年12月担任公司董事会成员。在加入Ocera之前，Grais博士曾于2005年5月至2011年2月担任风险投资公司InterWest Partners的管理成员。从1998年7月到2003年7月，Grais博士是SGX Pharmaceuticals Inc.的创始人和执行副总裁，SGX Pharmaceuticals Inc.是一家专注于癌症新疗法的药物发现公司。在此之前，她是Wilson Sonsini Goodrich & Rosati的公司律师，在风险融资、公开发行和战略合作伙伴关系等领域执业。在从事法律工作之前，Grais博士曾在加州大学旧金山分校担任内科和重症监护的临床助理教授。她目前在公共合同研究机构ICON plc、私营医疗保健服务公司Collective Health和私营生物技术公司Iolyx Therapeutics，Inc.的董事会任职。Grais博士获得了耶鲁大学的学士学位、耶鲁大学医学院的医学博士学位和斯坦福大学法学院的法学博士学位。
Linda S. Grais,has served as a member of Corvus Pharmaceuticals, Inc. Board since January 2019. Dr. Grais previously served as President and Chief Executive Officer of Ocera Therapeutics, Inc. from June 2012 to December 2017 and as a member of its board of directors from January 2008 through December 2017. Prior to her employment by Ocera, Dr. Grais served as a managing member at InterWest Partners, a venture capital firm, from May 2005 until February 2011. From July 1998 to July 2003, Dr. Grais was a founder and executive vice president of SGX Pharmaceuticals Inc., a drug discovery company focusing on new treatments for cancer. Prior to that, she was a corporate attorney at Wilson Sonsini Goodrich & Rosati, where she practiced in such areas as venture financings, public offerings and strategic partnerships. Before practicing law, Dr. Grais worked as an assistant clinical professor of Internal Medicine and Critical Care at the University of California, San Francisco. She currently serves on the board of directors of ICON plc, a public contract research organization, Collective Health, a private healthcare services company and Iolyx Therapeutics, Inc., a private biotechnology company. Dr. Grais received a B.A. from Yale University, an M.D. from Yale Medical School and a J.D. from Stanford Law School.- Linda S. Grais，自2019年1月起担任Corvus Pharmaceuticals, Inc.董事会成员。Grais博士此前于2012年6月至2017年12月担任Ocera医疗公司总裁兼首席执行官，并于2008年1月至2017年12月担任公司董事会成员。在加入Ocera之前，Grais博士曾于2005年5月至2011年2月担任风险投资公司InterWest Partners的管理成员。从1998年7月到2003年7月，Grais博士是SGX Pharmaceuticals Inc.的创始人和执行副总裁，SGX Pharmaceuticals Inc.是一家专注于癌症新疗法的药物发现公司。在此之前，她是Wilson Sonsini Goodrich & Rosati的公司律师，在风险融资、公开发行和战略合作伙伴关系等领域执业。在从事法律工作之前，Grais博士曾在加州大学旧金山分校担任内科和重症监护的临床助理教授。她目前在公共合同研究机构ICON plc、私营医疗保健服务公司Collective Health和私营生物技术公司Iolyx Therapeutics，Inc.的董事会任职。Grais博士获得了耶鲁大学的学士学位、耶鲁大学医学院的医学博士学位和斯坦福大学法学院的法学博士学位。
- Linda S. Grais,has served as a member of Corvus Pharmaceuticals, Inc. Board since January 2019. Dr. Grais previously served as President and Chief Executive Officer of Ocera Therapeutics, Inc. from June 2012 to December 2017 and as a member of its board of directors from January 2008 through December 2017. Prior to her employment by Ocera, Dr. Grais served as a managing member at InterWest Partners, a venture capital firm, from May 2005 until February 2011. From July 1998 to July 2003, Dr. Grais was a founder and executive vice president of SGX Pharmaceuticals Inc., a drug discovery company focusing on new treatments for cancer. Prior to that, she was a corporate attorney at Wilson Sonsini Goodrich & Rosati, where she practiced in such areas as venture financings, public offerings and strategic partnerships. Before practicing law, Dr. Grais worked as an assistant clinical professor of Internal Medicine and Critical Care at the University of California, San Francisco. She currently serves on the board of directors of ICON plc, a public contract research organization, Collective Health, a private healthcare services company and Iolyx Therapeutics, Inc., a private biotechnology company. Dr. Grais received a B.A. from Yale University, an M.D. from Yale Medical School and a J.D. from Stanford Law School.